awmsg logo



semaglutide (Ozempic®)


Reference No. 1842

Publication date:
06/11/2018


Appraisal information

semaglutide (Ozempic®) 1.34 mg/ml solution for injection


Company: Novo Nordisk Ltd
BNF category: Endocrine system
NMG meeting date: 05/09/2018
AWMSG meeting date: 17/10/2018
   
   
Submission Type: Full Submission
Status: Recommended with restrictions
Advice No: 1618
Ratification by Welsh Government: 02/11/2018

Current Progress


Submission
received
NMG
meeting
AWMSG
meeting
Ratification by
Welsh Government

AWMSG advice

Semaglutide (Ozempic®) is recommended as an option for restricted use within NHS Wales for the treatment of insufficiently controlled type 2 diabetes mellitus in adults as an add-on therapy to oral antidiabetic medicines or basal insulin. Semaglutide (Ozempic®) is not recommended for use within NHS Wales as monotherapy when metformin is considered inappropriate due to intolerance or contraindications.
Final Appraisal Recommendation (FAR)
Download
AWMSG Secretariat Appraisal Report (ASAR)
Download